期刊文献+

阿霉素脂质体的制备及对MCF-7/DOX作用的考察 被引量:6

Preparation of doxorubicin liposome and their effect on human MCF-7
下载PDF
导出
摘要 目的:制备阿霉素(Doxorubicin,DOX)脂质体,并考察其对耐阿霉素的人乳腺癌细胞(MCF-7/DOX)的作用。方法:采用硫酸铵梯度法制备脂质体;采用MTT法考察DOX脂质体对MCF-7/DOX的细胞毒性和逆转多药耐药(Multydrug resistance,MDR)的效果。结果:阿霉素的平均包封率为90.77%。脂质体的细胞毒性实验结果显示,DOX脂质体的IC50比游离DOX小4倍;DOX脂质体对MCF-7/DOX的逆转倍数是游离DOX的4倍。结论:硫酸铵梯度法适用于制备DOX脂质体,其具有较好的细胞毒性作用及一定的逆转MCF-7/DOXMDR的作用。 Objective : To prepare doxorubicin liposome and investigate its effect on human MCF-7 in vitro. Methods: DOX liposome was prepared by ( NH4 )2SO4-gradient method.The MTT method was used to test cytotoxicity and reverse muhidrug resistance of DOX liposome on MCF-7/DOX. Results: DOX was encapsulated by 90.77%. The results of liposome MTT experiment suggested that IC50 of free DOX was 4 times bigger than DOX liposome.The DOX liposomes' reversing effect on MDR was 4 times as much as that of free DOX. Conclusion:The method of (NH4)2SO4 gradient is suitable for producing DOX liposome and it has better cytotoxicity and reversing MDR effect on MCF-7 than free DOX.
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2009年第3期329-331,共3页 Journal of Chongqing Medical University
关键词 阿霉素脂质体 硫酸铵梯度 多药耐药 人乳腺癌细胞 DOX liposome ( NH4 )2SO4 gradient method Muhidrug resistance MCF-7
  • 相关文献

参考文献4

  • 1柯爱武,李羲.脂质体逆转肿瘤多药耐药研究进展[J].国外医学(预防.诊断.治疗用生物制品分册),2005,28(2):75-80. 被引量:6
  • 2Grant G J,Baronholz Y,Bolotin E M,et al. A novel liposomal bupivacaine formulation to produce uhralong-acting analgesia[J]. Anesthesiolongy, 2004,101( 1 ) : 133-137.
  • 3Wang J, Goh B, Lu W, et al. In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells[J]. Biol Pharm Bull, 2005,28 (5) : 822-828.
  • 4Lo Y L. Phospholipids as muhidrug resistance modulators of the transport of epirubiein in human intestinal epithelial Caeo-2 cell layers and everted gut sacs of rats[J]. Biochem Pharmacol, 2000 , 60 ( 9 ) : 1381-1390.

二级参考文献29

  • 1Bosch I, Dunussi-Joannopoulos K, Wu RL, et al. Phosphatidylcholine and Phospha-tidylethanolamine Behave as Substrates of the Human MDR1 P-Glycoprotein. Biochemistry, 1997,36:5685-5694.
  • 2Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco2 cell layers and everted gut sacs of rats. Biochem Pharmacol,2000,60:1381-1390.
  • 3Michieli M, Damiani D, Ermacora A, et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol, 1999,106:92-99.
  • 4Merlin JL, Marchal S, Ramacci C, et al. Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia. Int J Hyperthermia, 1995,11: 855-865.
  • 5Needham D, Anyarambhatla G, Kong G, et al. A new temperature-sensitive liposome for use with mild hyperthermia:characterization and testing in a human tumor xenograft model. Cancer Res, 2000,60:1197-1201.
  • 6Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev, 2001,53:285-305.
  • 7Krishna R, Mayer LD. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res, 1999,19 :2885-2891.
  • 8Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res, 1997,57:5246-5253.
  • 9Lo YL, Liu FI, Yang JM, et al. Reversal of multidrug resistance to epirubicin by cyclosporin Ain liposomes or intralipid.Anticancer Res, 2001,21 .. 445-450.
  • 10Sadasivan R, Morgan R, Fabian C, et al. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett, 1991,57:165-171.

共引文献5

同被引文献100

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部